Habte Yimer is an Oncology physician affiliated with The University of Texas at Tyler. OpenAlex indexes 121 publications with 4,225 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
501 Saunders Ave Ste 200
Tyler, TX 757027524
Telephone
903-579-9800Provider last certified this registry record 8 Jul 2023.
Industry payments
66 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202546 payments$61,476openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202538 payments$41,293openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202537 payments$30,170openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
60.4%PD-1 inhibitor24.9%Pembrolizumab68%Nivolumab26%Atezolizumab7%Part B, office-administered≥47 patientsPlatinum-based Drug11%Oxaliplatin96%Carboplatin3%Cisplatin1%Part B, office-administered≥49 patients+ 17 more classes in this area
Blood & clotting
16.5%Parenteral Iron Replacement8.1%Iron sucrose100%Part B, office-administered≥30 patientsErythropoiesis-stimulating Agent7.2%Darbepoetin alfa100%Part B, office-administered≥20 patients+ 3 more classes in this area
Metabolism & gastrointestinal
12.9%Other antiemetics9.2%Fosaprepitant100%Part B, office-administered≥47 patientsSerotonin-3 Receptor Antagonist1.9%Palonosetron hcl58%Granisetron hydrochloride39%Ondansetron Odt2%Ondansetron Hcl1%Part D + Part B≥83 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Jarett Berry, MD
The University of Texas at Tyler
Paul Detwiler, MD
The University of Texas at Tyler
Megan Devine, MD
The University of Texas at Tyler
Shilpa Chitnis, MD
The University of Texas at Tyler
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”